Glucose transporter type1 (GLUT-1) deficiency.
D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D001205:Ascorbic Acid / Q000378:metabolism; D001812:Blood-Brain Barrier / Q000503:physiopathology; D002110:Caffeine / Q000009:adverse effects; D000697:Central Nervous System Stimulants / Q000009:adverse effects; D002878:Chromosomes, Human, Pair 1; D005947:Glucose / Q000134:cerebrospinal fluid; D051272:Glucose Transporter Type 1; D006801:Humans; D007662:Ketosis / Q000209:etiology; D007859:Learning Disabilities / Q000209:etiology* / Q000378:metabolism; D009004:Monosaccharide Transport Proteins / Q000172:deficiency*; D009154:Mutation; D010634:Phenobarbital / Q000009:adverse effects; D012640:Seizures / Q000209:etiology; D008063:Thioctic Acid / Q000627:therapeutic use
D000927:Anticonvulsants; D000975:Antioxidants; D000697:Central Nervous System Stimulants; D051272:Glucose Transporter Type 1; D009004:Monosaccharide Transport Proteins; C495677:SLC2A1 protein, human; D002110:Caffeine; D008063:Thioctic Acid; D005947:Glucose; D001205:Ascorbic Acid; D010634:Phenobarbital